Global Vaccine and Immunization Research Forum - Webinar March 3, 2022
the Global Vaccine and Immunization Research Forum (GVIRF) collaboration, NIAID, the Bill & Melinda Gates Foundation, and World Health Organization are organizing a webinar; information, including a link to register may be found below, on in the attached agenda and flyer.
Webinar Title: Malaria Vaccine R&D and Immunization: Lessons Learned and Considerations for Global Health Impact
When: 9:00am-12:00pm EST, March 3, 2022
Registration (no-cost): https://web.cvent.com/event/1d3c16a1-bf7b-4678-a4c0-99e02b71d379/summary
Purpose: This webinar will showcase challenges and lessons learned from development and deployment of a vaccine against a pathogen with complicated biology and without a dual market, and will involve discussion of strategies and considerations for future malaria vaccine research and development.
Webinar goal:
Significant challenges affect the development and implementation of vaccines targeting diseases prevalent in low- and middle-income countries. The first-generation malaria vaccine RTS, S/ASO1 is an important advance in combatting a difficult pathogen and illustrates critical obstacles facing the vaccine and immunization communities. Using RTS, S/AS01 as a case study, this webinar will explore lessons learned and discuss vaccine R&D considerations for malaria and other diseases of global health importance prevalent in resource-limited settings.
Topics:
- The RTS, S/AS01 vaccine and lessons learned
- Future malaria R&D priorities and strategies
- Vaccine development hurdles and challenges
- Implementation and distribution considerations
- Manufacturing and accessibility impediments
- Safety and regulatory concerns
- Resources and global collaboration
For more information, please contact
Annie Mo, Ph.D.
Senior Program Officer
Parasitology and International Programs Branch
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases
5601 Fishers Lane, Room 8A29
Rockville, MD 20852 phone 240.627.3320
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
